Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med.2002;346:896-903.
2.
Olschewski H. , Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med.2002;347:322-329.
3.
Simonneau G. , Barst RJ, Galie N., et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med.2002; 165:800-804.
4.
Galie N., Ghofrani HA, Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension . N Engl J Med.2005;353:2148-2157.
5.
Simonneau G., Galie N., Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol.2004;43(suppl):5-12.
6.
Newman JH, Wheeler L., Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med.2001;345:319-324.
7.
Thomson JR, Machado RD, Pauciulo MW, et al., Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet.2000;37:741-745.
8.
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. J Med Genet.2000;26: 81-84.
9.
Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med.2001;345:325-334.
10.
Du L., Sullivan CC, Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med.2003;348:500-509.
11.
Pengo V., Lensing A., Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med.2004;350:2257-2264.
12.
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med.1996;334:296-301.
13.
Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol.2002;40:780-788.
14.
Farber HW, Loscalzo J.Pulmonary arterial hypertension. N Engl J Med.2004;351:1655-1665.
15.
Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest.2004;126(Suppl): 35-62.
